<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621280</url>
  </required_header>
  <id_info>
    <org_study_id>COR-2017-OLE</org_study_id>
    <nct_id>NCT03621280</nct_id>
  </id_info>
  <brief_title>Open-label Treatment in Cushing's Syndrome</brief_title>
  <acronym>OPTICS</acronym>
  <official_title>An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cortendo AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cortendo AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term, open-label extension study of levoketoconazole in subjects with&#xD;
      endogenous Cushing's Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a long-term, OLE study of levoketoconazole in subjects with endogenous CS who have&#xD;
      completed one or both parent studies or otherwise potentially qualify for this study, as&#xD;
      defined in the eligibility criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label Extension Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from Baseline in 24-h UFC</measure>
    <time_frame>From Baseline to final study visit or up to a maximum of 3 years, whichever comes first.</time_frame>
    <description>Changes or shifts from baseline in mUFC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline in Late Night Salivary Cortisol</measure>
    <time_frame>From Baseline to final study visit or up to a maximum of 3 years, whichever comes first.</time_frame>
    <description>Changes or shifts from baseline in late night salivary cortisol levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline in AEs/SAEs/AESI as assessed by CTCAE V4.03</measure>
    <time_frame>From Baseline to final study visit or up to a maximum of 3 years, whichever comes first.</time_frame>
    <description>Changes from Baseline in the incidence and severity of AEs, SAEs, AESIs</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cushing Syndrome</condition>
  <condition>Cushing Disease</condition>
  <arm_group>
    <arm_group_label>Levoketoconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levoketoconazole taken twice daily up to 1200 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levoketoconazole</intervention_name>
    <description>Levoketoconazole up to 1200 mg daily</description>
    <arm_group_label>Levoketoconazole</arm_group_label>
    <other_name>COR-003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completed the Extended Evaluation Phase of Study COR-2012-01 (i.e. M12)&#xD;
&#xD;
          2. Completed the Restoration Phase of Study COR-2017-01 (i.e. RES2)&#xD;
&#xD;
             NOTE: Subjects meeting criteria 1 or 2 above who have had a break in therapy may be&#xD;
             eligible only after discussion with the Medical Monitor. If eligible, such subjects&#xD;
             may require re-establishment of the Therapeutic Dose via titration. All subjects who&#xD;
             have had a break in therapy should be discussed with the Medical Monitor to determine&#xD;
             the starting dose of levoketoconazole. Prior to resuming treatment with&#xD;
             levoketoconazole, other therapies for Cushing's Syndrome must undergo an appropriate&#xD;
             washout period, with minimum durations as follows:&#xD;
&#xD;
               -  Ketoconazole or metyrapone: 2 weeks;&#xD;
&#xD;
               -  Dopamine agonists: bromocriptine (2 weeks), cabergoline (8 weeks);&#xD;
&#xD;
               -  Octreotide acetate LAR, lanreotide Autogel, pasireotide LAR: 12 weeks;&#xD;
&#xD;
               -  Lanreotide SR: 8 weeks;&#xD;
&#xD;
               -  Octreotide acetate (immediate release) or short-acting pasireotide: 1 week;&#xD;
&#xD;
               -  Mifepristone (RU 486, KORLYM): 4 weeks;&#xD;
&#xD;
               -  Megestrol acetate or medroxyprogesterone acetate (and selected other synthetic&#xD;
                  progestins): 6 weeks.&#xD;
&#xD;
          3. Currently in a named patient program or other Expanded Access Program receiving&#xD;
             levoketoconazole&#xD;
&#xD;
          4. Were levoketoconazole-naïve prior to entry and received early rescue therapy with&#xD;
             open-label levoketoconazole in Study COR-2017-01.&#xD;
&#xD;
          5. Achieved a clinically meaningful partial response (with reduction of UFC) in Study&#xD;
             COR-2017-01 at dose level 7 or at a maximally tolerated dose of levoketoconazole but&#xD;
             did not meet the randomization criteria for Study COR-2017-01 at the end of the Dose&#xD;
             Titration and Maintenance Phase when randomization was open.&#xD;
&#xD;
          6. Were levoketoconazole-naïve prior to entry and were enrolled in Study COR-2017-01 in&#xD;
             the Dose Titration and Maintenance Phase when randomization was closed. (NOTE: Such&#xD;
             subjects must receive at least 1 dose of levoketoconazole before transitioning to this&#xD;
             study.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Discontinued levoketoconazole while participating in Study COR-2012-01 or Study&#xD;
             COR-2017-01 or a named patient program or other Expanded Access program, due to safety&#xD;
             or tolerability concerns or lack of efficacy.&#xD;
&#xD;
          2. Scheduled for surgery for treatment of CS or received surgery for treatment of CS&#xD;
             within the 6 weeks prior to Screening.&#xD;
&#xD;
          3. Treated with mitotane within 6 months prior to enrollment.&#xD;
&#xD;
          4. History of malignancy, including adrenal or pituitary carcinomas (other than low-risk,&#xD;
             well-differentiated carcinomas of thyroid, breast or prostate that are very unlikely&#xD;
             to require further treatment in the opinion of the treating physician, or squamous&#xD;
             cell or basal cell carcinoma of the skin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredric Cohen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cortendo AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Center for Diabetes and Endocrine Care</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico HSC - HSC Sponsored Projects Office</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sveti Georgy University Hospital Clinic of Endocrinology and Metabolic Diseases</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandovska University Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Specialized Hospital for Active Treatment in Endocrinology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Evangelismos Department of Endocrinology and Diabete</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital Endocrinology and Diabetes Department</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. Belgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center Endocrinology Institute</name>
      <address>
        <city>Haifa</city>
        <zip>34802</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Campus</name>
      <address>
        <city>Petah tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv-Sourasky Medical Center Institute Endocrinology Metabolism &amp; Hypertension</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Endocrinologia malattie del Metabolismo</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico G. Martino Sezione di Endocrinologia</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Sergio Pansini 5 Uni Naples FedericoII Dept of Molecular&amp;Clinical Endocrinology&amp;Oncology</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turin</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki</name>
      <address>
        <city>Łódź</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Endocrinologie C.I. Parhon</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj-Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean Mures</name>
      <address>
        <city>Târgu-Mureş</city>
        <zip>540139</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universidad De La Ribera</name>
      <address>
        <city>Alzira</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

